Back

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer

2024-09-12 oncology Title + abstract only
View on medRxiv
Show abstract

Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yet efficacy remains low. The current approach for predicting the likelihood of response to ICB is a single proportional biomarker (PD-L1) expressed in immune and tumor cells (Combined Positive Score, CPS) without differentiation by cell type, potentially explaining its limited predictive value. Tertiary Lymphoid Structures (TLS) have shown a stronger association with ...

Predicted journal destinations